The assay amplified the 30 bp deletion NPC genetic biomarker in all MT variant FNA and AB samples from NPC patients, and this developed assay was able to differentiate between WT variant from MT variant among NPC AB and FNA samples, as shown in Figure 5. The gene discussed is NPC1; the disease is nasopharyngeal carcinoma.